Tizanidine
Product Images NDC 67296-1417

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 67296-1417). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Epm 15 Ct (67296 1417 7)

Label for Tizanidine 4 mg tablets, containing 15 tablets, labeled as Rx only. Manufactured by Dr. Reddy's Laboratories Limited in India and distributed by RedPharm Drug, Inc. in Eden Prairie, MN. The label includes the NDC 67296-1417-7, lot number, and expiration date of 04/23, with storage instructions at controlled room temperature 20-25°C (68-77°F).*

FDA Label Image

Container1 (Container1)

Label for Tizanidine Tablets, USP 2 mg, showing 150 tablets per package. The label states the tablets are prescription only and not interchangeable with Tizanidine Capsules. It includes active ingredient information for each tablet, storage instructions, and manufacturer details for Dr. Reddy's Laboratories Limited, India. The label also features NDC, barcode, and trademark marks.*

FDA Label Image

Container2 (Container2)

Label for Tizanidine Tablets USP 2 mg, containing 150 tablets. The label notes that these tablets are not interchangeable with Tizanidine Capsules. It is labeled Rx Only and manufactured by Dr. Reddy's Laboratories Limited. The label includes dosage information per tablet and storage instructions, alongside a barcode and NDC 55111-179-15.*

FDA Label Image

Container3 (Container3)

Label for Tizanidine Tablets USP 4 mg, 150 tablets per bottle, manufactured by Dr. Reddy's Laboratories Limited. The label includes active ingredient strength information and warnings about interchangeability with Tizanidine Capsules. The label also features storage instructions and a barcode.*

FDA Label Image

Container4 (Container4)

Label for Tizanidine Tablets, USP 4 mg by Dr. Reddy's Laboratories Limited. The label includes dosage strength (4 mg), quantity (150 tablets), storage instructions, and a warning that tablets are not interchangeable with capsules. The label also displays the NDC 55111-180-15 and manufacturing details from India.*

FDA Label Image

Fig1 (Fig1)

A pharmacokinetic line graph showing plasma tizanidine concentration (ng/mL) versus hours from dosing. The graph compares 2x 4 mg tizanidine tablets and capsules with and without food, illustrating differences in drug concentration over 24 hours post-dosing.*

FDA Label Image

Fig2 (Fig2)

A line graph showing improvement in Ashworth Score over time (hours post-dose) comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The 16 mg dose shows the greatest improvement, peaking around 2 hours, followed by 8 mg and placebo, which shows minimal improvement.*

FDA Label Image

Fig3 (Fig3)

A line graph comparing improvement in Ashworth Score between tizanidine (mean dose 28.8 mg) and placebo groups over time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The vertical axis measures improvement in Ashworth Score, with tizanidine consistently showing greater improvement than placebo.*

FDA Label Image

Structure (Structure)

Chemical structure of tizanidine hydrochloride, illustrating its molecular framework including a chlorinated aromatic ring and two fused ring systems.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.